Vol. 19/No. 10 | OncologyLive

Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma

May 25, 2018

The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.

Expert Panel Says Evidence Does Not Yet Support Most ctDNA Testing Outside of Clinical Trials

May 18, 2018

There is very little evidence of clinical validity or clinical utility to justify the widespread use of circulating tumor DNA assays in most patients with advanced cancer, according to a panel of experts from ASCO and the College of American Pathologists

Blueprint for Tackling Toxicities From Checkpoint Blockade Agents Is Introduced

May 14, 2018

The National Comprehensive Cancer Network has developed its first set of recommendations to help clinicians manage toxicities in the recognition of the variety of immune-related adverse events that patients receiving checkpoint blockade immunotherapy may experience.

NCCN Crafts First Guidelines for Uveal Melanoma

May 13, 2018

The unique biological characteristics of uveal melanoma have prompted the National Comprehensive Cancer Network to develop the first set of guidelines for the diagnosis and management of the rare cancer.

It's Fast-Forward for Cancer Drugs

May 11, 2018

More than a third of the new indications for oncology drugs that became available for patient care during the past 25 years entered clinical practice as a result of the FDA’s accelerated approval program.